文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

间充质干细胞治疗对脓毒性休克患者全身细胞因子水平的影响:一项1期剂量递增安全性试验

Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients.
PubMed 文献 · Crit Care Med · 2019-01-01
一句话结论脓毒性休克患者单次输注异体骨髓间充质干细胞最高3百万个/kg未加剧血浆细胞因子升高,与安全性反应一致。

该研究为首次在人体进行的脓毒性休克异体间充质干细胞临床试验的细胞因子分析。干预队列9例接受单次0.3、1.0或3.0百万个/kg间充质干细胞(每剂量3例),观察队列21例未接受间充质干细胞。在基线及输注后1、4、12、24、72小时采集血浆,检测49种分析物。干预队列与观察队列之间未检测到广谱促炎细胞因子和生物标志物的显著升高;按剂量分层显示患者特异性和剂量依赖性的细胞因子扰动,包括促炎细胞因子(如白细胞介素-1β、白细胞介素-2、白细胞介素-6、白细胞介素-8和单核细胞趋化蛋白1)早期但短暂的抑制,提示间充质干细胞治疗可能改变先天免疫反应和脓毒症生物学。

要点

  • 脓毒性休克患者单次输注异体骨髓间充质干细胞最高3百万个/kg,未加剧血浆细胞因子升高,与安全性反应一致。
  • 干预队列9例(0.3、1.0、3.0百万个/kg各3例)与观察队列21例相比,广谱促炎细胞因子和生物标志物无显著升高。
  • 按剂量分层显示患者特异性和剂量依赖性的细胞因子扰动,包括白细胞介素-1β、白细胞介素-2、白细胞介素-6、白细胞介素-8和单核细胞趋化蛋白1的早期但短暂抑制。
  • 作者认为间充质干细胞治疗可能改变先天免疫反应和脓毒症生物学,并支持在更大规模随机对照试验中进一步研究。

适用人群与场景

  • 脓毒性休克患者,干预队列9例接受间充质干细胞,观察队列21例未接受间充质干细胞。

处置流程与药物剂量

  • 干预队列接受单次异体骨髓来源间充质干细胞输注,剂量为0.3、1.0或3.0百万个/kg体重(每剂量3例)。
  • 在基线(0小时)及输注/入组后1小时、4小时、12小时、24小时、72小时采集系列血浆样本。
  • 检测49种分析物,主要包括细胞因子和几种生物标志物。

研究设计与关键结果

  • 1期剂量递增试验,干预队列9例,观察队列21例,干预为单次异体骨髓来源间充质干细胞输注(0.3、1.0、3.0百万个/kg,每剂量3例)。
  • 干预队列与观察队列之间未检测到广谱促炎细胞因子和生物标志物的显著升高。
  • 按间充质干细胞剂量分层显示患者特异性和剂量依赖性的细胞因子扰动,包括白细胞介素-1β、白细胞介素-2、白细胞介素-6、白细胞介素-8和单核细胞趋化蛋白1的早期但短暂抑制。

证据类型、等级与局限

  • 证据类型:1期剂量递增试验。
  • 作者认为间充质干细胞治疗可能改变先天免疫反应和脓毒症生物学,并支持在更大规模随机对照试验中进一步研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 原文结论:单次输注最高3百万个/kg异体间充质干细胞未加剧脓毒性休克患者血浆细胞因子升高,与安全性反应一致;作者支持在更大规模随机对照试验中进一步研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: Cellular Immunotherapy for Septic Shock is the first-in-human clinical trial evaluating allogeneic mesenchymal stem/stromal cells in septic shock patients. Here, we sought to determine whether plasma cytokine profiles may provide further information into the safety and biological effects of mesenchymal stem/stromal cell treatment, as no previous study has conducted a comprehensive analysis of circulating cytokine levels in critically ill patients treated with mesenchymal stem/stromal cells.

DESIGN: Phase 1 dose-escalation trial.

PATIENTS: The interventional cohort (n = 9) of septic shock patients received a single dose of 0.3, 1.0, or 3.0 million mesenchymal stem/stromal cells/kg body weight (n = 3 per dose). The observational cohort received no mesenchymal stem/stromal cells (n = 21).

INTERVENTIONS: Allogeneic bone marrow-derived mesenchymal stem/stromal cells.

MEASUREMENTS AND MAIN RESULTS: Serial plasma samples were collected at study baseline prior to mesenchymal stem/stromal cell infusion (0 hr), 1 hour, 4 hours, 12 hours, 24 hours, and 72 hours after mesenchymal stem/stromal cell infusion/trial enrollment. Forty-nine analytes comprised mostly of cytokines along with several biomarkers were measured. We detected no significant elevations in a broad range of pro-inflammatory cytokines and biomarkers between the interventional and observational cohorts. Stratification of the interventional cohort by mesenchymal stem/stromal cell dose further revealed patient-specific and dose-dependent perturbations in cytokines, including an early but transient dampening of pro-inflammatory cytokines (e.g., interleukin-1β, interleukin-2, interleukin-6, interleukin-8, and monocyte chemoattractant protein 1), suggesting that mesenchymal stem/stromal cell treatment may alter innate immune responses and underlying sepsis biology.

CONCLUSIONS: A single infusion of up to 3 million cells/kg of allogeneic mesenchymal stem/stromal cells did not exacerbate elevated cytokine levels in plasma of septic shock patients, consistent with a safe response. These data also offer insight into potential biological mechanisms of mesenchymal stem/stromal cell treatment and support further investigation in larger randomized controlled trials.

来源:Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Schlosser K, Wang JP, Dos Santos C, et al. Effects of Mesenchymal Stem Cell Treatment on Systemic Cytokine Levels in a Phase 1 Dose Escalation Safety Trial of Septic Shock Patients. Crit Care Med. 2019. PMID: 30720538. doi:10.1097/CCM.0000000000003657

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。